口服司美格鲁肽治疗可降低2型糖尿病患者的心血管事件：解读该研究的精髓
Oral Semaglutide Therapy Reduces Cardiovascular Events in Patients with Type 2 Diabetes: Deciphering the Soul of the Study.
作者信息
Jialal Ishwarlal, Olatunbosun Samuel T
机构信息
Departments of Internal Medicine and Pathology, UC Davis School of Medicine, Davis, CA 95618, USA.
Endocrinology Section, Medical Service, VA Northern California Health Care System, Mather, CA 95655, USA.
出版信息
J Clin Med. 2025 May 11;14(10):3335. doi: 10.3390/jcm14103335.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-IRAs) have become pivotal in the management of type 2 diabetes mellitus (T2DM) [...].
摘要
胰高血糖素样肽-1受体激动剂（GLP-IRAs）已成为2型糖尿病（T2DM）管理的关键药物[……]
相似文献
1
Oral Semaglutide Therapy Reduces Cardiovascular Events in Patients with Type 2 Diabetes: Deciphering the Soul of the Study.口服司美格鲁肽治疗可降低2型糖尿病患者的心血管事件：解读该研究的精髓
J Clin Med. 2025 May 11;14(10):3335. doi: 10.3390/jcm14103335.
2
Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).在 2 型糖尿病患者中比较每周一次胰高血糖素样肽-1 受体激动剂（OW GLP-1RAs）与二肽基肽酶-4 抑制剂（DPP-4is）的降糖和减重效果的真实世界疗效（RELATE）。
Clin Drug Investig. 2024 Apr;44(4):271-284. doi: 10.1007/s40261-024-01354-2. Epub 2024 Mar 20.
3
Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review.口服司美格鲁肽，2 型糖尿病管理的新选择：叙述性综述。
Adv Ther. 2020 Oct;37(10):4165-4174. doi: 10.1007/s12325-020-01478-9. Epub 2020 Sep 4.
4
Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.胰高血糖素样肽-1（GLP-1）受体激动剂与 2 型糖尿病患者的心血管事件：一项双盲、随机、安慰剂对照临床试验的荟萃分析。
BMC Endocr Disord. 2022 May 12;22(1):125. doi: 10.1186/s12902-022-01036-0.
5
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.GLP-1 受体激动剂在 2 型糖尿病治疗中的应用——最新进展。
Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14.
6
Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.口服司美格鲁肽：用于治疗 2 型糖尿病的首个口服 GLP-1 受体激动剂。
Ann Pharmacother. 2020 May;54(5):478-485. doi: 10.1177/1060028019889064. Epub 2019 Nov 19.
7
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者的心血管风险降低：这是一类药物的作用吗？
Curr Cardiol Rep. 2018 Sep 26;20(11):113. doi: 10.1007/s11886-018-1051-2.
8
The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs.口服司美格鲁肽在印度临床环境中管理 2 型糖尿病的作用：满足未满足的需求。
Diabetes Metab Syndr. 2022 Jun;16(6):102508. doi: 10.1016/j.dsx.2022.102508. Epub 2022 May 23.
9
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.2型糖尿病患者使用长效注射和口服胰高血糖素样肽-1受体激动剂的心血管和肾脏结局及死亡率：一项随机试验的系统评价和荟萃分析
Diabetes Care. 2025 May 1;48(5):846-859. doi: 10.2337/dc25-0241.
10
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.口服司美格鲁肽对 2 型糖尿病合并已确诊的动脉粥样硬化性心血管疾病和/或慢性肾脏病患者心血管结局的影响：一项随机试验 SOUL 的设计和基线特征。
Diabetes Obes Metab. 2023 Jul;25(7):1932-1941. doi: 10.1111/dom.15058. Epub 2023 Apr 11.
本文引用的文献
1
The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review.口服司美格鲁肽对2型糖尿病患者心血管危险因素的影响：一项系统评价
J Clin Med. 2025 Mar 25;14(7):2239. doi: 10.3390/jcm14072239.
2
Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials.口服司美格鲁肽治疗2型糖尿病的临床开发：聚焦于早期临床试验
Transl Clin Pharmacol. 2025 Mar;33(1):1-9. doi: 10.12793/tcp.2025.33.e3. Epub 2025 Mar 20.
3
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.口服司美格鲁肽与高危2型糖尿病患者的心血管结局
N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29.
4
Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes.非胰岛素药物治疗2型糖尿病对血糖、心肾及体重的影响
J Clin Endocrinol Metab. 2025 Feb 25;110(Supplement_2):S147-S158. doi: 10.1210/clinem/dgae817.
5
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.9. 血糖治疗的药理学方法：2025年糖尿病护理标准
Diabetes Care. 2025 Jan 1;48(Supplement_1):S181-S206. doi: 10.2337/dc25-S009.
6
Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice.口服司美格鲁肽治疗2型糖尿病的真实世界证据。临床实践的叙述性综述
Clin Ther. 2025 Jan;47(1):102-110. doi: 10.1016/j.clinthera.2024.11.005. Epub 2024 Nov 29.
7
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
8
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.口服司美格鲁肽与 2 型糖尿病患者的心血管结局。
N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.
9
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
10
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
Zotero 插件